Participants, December 2003

The information provided below is based on details submitted by delegates to the first Oxford Vision 2020 meeting in December 2003. This is intended to provide highlights only, not a full CV.

Danny Abelson
President, The Abelson Company

Founder and leader of a creative consultancy based in New York and London, which works with a variety of clients to define strategic visions and brand positioning – and to create the communications which bring brands to life.

Current clients include: The Metropolitan Museum of Art, The New York Philharmonic, New Skies Satellite, Physicians for Human Rights, and Novo Nordisk. In the past, the Abelson Company has also worked with Chase, Seagram, Zurich Financial Services, The Body Shop, MTV and ESPN.

Boris Azaïs
IFPMA Fellow, Director of External Policy International Federation of Pharmaceutical Manufacturers Associations

Boris Azaïs is a lawyer on secondment from Merck Sharp & Dohme (MSD) for two years.

Previously, he acted as head of legal affairs for the company in Asia and Africa, and was responsible for designing the framework of the Accelerating Access initiative in Africa. His legal work in this area was then used by Merck for similar initiatives related to increased access to anti retroviral medicines in other parts of the world (Central Eastern Europe and the Caribbean).

Professor John Bell Chairman, Oxford Vision 2020 Conference
Regius Professor of Clinical Medicine, University of Oxford

In his current position, Professor Bell contributes to the development of scientific strategy in Oxford, working with other organisations on a national and international level. Professor Bell is a member of Council of the University of Oxford and a trustee of The Rhodes Trust.

In the past 10 years, prior to his current appointment, he served as Nuffield Professor of Clinical Medicine, University of Oxford, where he built up the largest biomedical research department in the United Kingdom. Professor Bell cofounded the Wellcome Trust Centre for Human Genetics in Oxford and is chairman of the Partnership Board that leads the Oxford Centre for Diabetes, Endocrinology and Metabolism.

Professor Bell’s research interests are focused on understanding the mechanisms involved in mediating disease, the genetic factors contributing to disease susceptibility and the molecular events associated with T cell activation through the T cell antigen receptor.

Dr Clement Bezold
President Institute for Alternative Futures (IAF)
IAF’s for-profit subsidiary, Alternative Futures Associates (AFA)

Dr Bezold established IAF in 1977 to encourage ‘Anticipatory Democracy’. IAF’s mission specifically is to help communities and organizations more wisely choose and create the future they prefer. Within that, Dr Bezold, personally, is a leading health futurist. He has developed concepts that have accurately described aspects of how health, health care systems and therapeutics will evolve.
He has consulted with both WHO/Geneva and the Pan American Health Organization (PAHO) on enhancing their ability to use health futures in their operations to support WHO’s vision of health for all. For the private sector he has led major efforts on the future of cancer and other chronic diseases, including a project on the future of diabetes for Novo Nordisk.

Dr Bezold has published extensively. He is also the government editor of The Futurist, and on the editorial or advisory boards of Technology Forecasting and Social Change, Foresight, Journal of Futures Studies, and Futures Survey.

Viggo Birch
Managing Director Novo Nordisk UK, Ireland, the Nordic Countries and Vice President Europe

In his current capacity, Mr Birch is responsible for all operations, marketing and sales within the Novo Nordisk territories listed. This follows 11 very successful years in Spain and Portugal, where Mr Birch was instrumental in building awareness of the dangers of Diabetes, and helped establish the Spanish Diabetes Association of whose Board he is still a member

An avowed European, having studied, lived and worked across the continent, but also graduating from the Wharton School of the University of Pennsylvania, Mr Birch finds time to be an advocate for people with diabetes across the continent, as well as represent his city of Copenhagen as one of its Goodwill Ambassadors.

Mark Blecher
National Treasury, Republic of South Africa

Olive Boles
Development Director for Healthy Eating, Active Living (HEAL) initiative
International Business Leaders Forum

Ms Boles’ project is a global partnership programme for business action on healthy eating and active living. This follows previous involvement with The Prince’s Foundation (HRH Prince Charles, the Prince of Wales) working on issues related to the built environment, urban regeneration and sustainable community development.
Ms Boles brought to both assignments her experiences in working within the UK’s National Health Service (NHS), as well as work on health promotion campaigns in the areas of HIV/AIDS, Smoking and CHD Prevention.

Hilary Bowker
Founder, Bowker Media + Communications
Moderator, Oxford Vision 2020 Conference

Hilary Bowker advises public and private sector organisations on communications strategy and moderates conferences, meetings and seminars.

As Senior European Anchor for CNN, Hilary interviewed and chaired debates between world leaders in politics, diplomacy, business, science, the arts, academia, industry and the military. Before joining CNN, Bowker was a London correspondent for ABC News.
Clients include: Ambrosetti; OFCOM (Switzerland), The World Bank; WHO; CIES – The Food Forum; The International Herald Tribune; The International Chamber of Commerce; The Royal Bank of Scotland; GAVI; UNICEF; OR Media; China Online; Forum 21; The International Youth Foundation; Olympic Aid and others.

Mrs Sissel Brinchmann
Director of European Public Affairs, Merck Sharp & Dohme (MSD), Europe, Middle East & Africa

In the past two years, Ms Brinchmann has been coordinating public affairs support across the entire Merck Sharp & Dohme range of activities in EMEA. This appointment follows 10 years in the company service, including a secondment to WHO on the Tobacco Free Initiative, and a stint serving in Brussels as the head of Public Affairs for Europe

Ms Brinchmann is a pharmacist by profession and training with teaching, writing and publishing experience and expertise spanning 25 plus years. Of major note is her service as the chief editor of a Norwegian medical publishing house, and as the Director of the Norwegian Association of Pharmaceutical Manufactures.

Mr. Richard Bumgarner
Independent consultant.
Richard’s thirty years experience at the World Bank and WHO inform his consulting assignments on such diverse areas as health policy, finance and economics with a variety of public and private sector clients.

Public-sector clients include the Rockefeller Foundation, the Global Fund Against AIDS, TB and Malaria, the Malaria Vaccine Initiative, the World Health Organisation, the World Bank, and the New York City Health Department.

In the past, Richard led an extensive study of the non-communicable diseases in China, helped to found the Global Tuberculosis Program and its strategy (DOTS) and developed multiple health programs in China, Indonesia, Mexico, India and parts of West Africa.

Dr Peter Byass
Umeaa University, Sweden, Aberdeen and Nottingham Universities, United Kingdom

Dr Byass is a specialist in international health issues and the epidemiology of health and disease in southern countries. His research interests are in the process of epidemiological transition, increasingly looking at the impact of non-communicable diseases in poorer societies.

A PhD in Public Health, Dr Byass professes a passion to correct the continuing injustice of the global north-south divide. This passion drives him to offer research training for southern cone scientists, as well as chair the Methodist Relief & Development Fund (MRDF).

Linda Carrier-Walker
International Council of Nurses

Dr Niels Christiansen
Vice President, Public Affairs, Nestlé SA

As Vice President of Public Affairs, Dr Christiansen co-chairs the Food Industry’s Global Task Force on Obesity, Nutrition and Health. He is also a Member of the Board of Directors of the International Cocoa Initiative, an industry-union-NGO Foundation working to improve working conditions in cocoa growing; and Vice-Chairman of the Industry Council for Development, an NGO working with WHO and FAO to improve food safety practice among health professionals and nutritionists.

Prior to joining Nestle, Dr Christiansen was a member of the Faculty of the Harvard University School of Public Health, department of Nutrition.

Professor Chunming Chen
Founding President, Chinese Centre for Disease Control and Prevention

Professor Chen has been focused on Population Nutrition and Nutrition Policy studies since 1982. and designed the current National Nutrition Surveillance System in China. She is the key Supervisor of the System.

She is an expert on nutrition status of children and general population in China, and on food consumption behaviour of the Chinese people during economic development.

On the international scene, Professor Chen has served on the WHO expert panel on nutrition, she was elected as Vice Chair of the FAO/WHO International Conference on Nutrition; she is a director of the International Life Science Institute, and a fellow of the International Union of Nutritional Sciences (IUNS).

As the recipient of the Gopalan Award of the Nutrition Society of India (2003), Professor Chen is also active in initiating the food fortification programme in China, and drives the Global Alliance for Improved Nutrition (GAIN) in her country.

Professor Chen is a widely published author, with over 50 publications in English and Chinese since 1990 alone.

Dr Denise Costa Coitinho
Senior Lecturer, Coordinator Food Security and Nutrition Policies Observatory, Public Policies Research Centre, University of Brasilia

Dr Coitinho served as the Director of the Food and Nutrition Policy Unit, Ministry of Health, Brazil until Feb 2003. In this capacity, she was responsible for restructuring of all food and nutrition work at federal level and the coordination of the process of formulation, implementation and evaluation of the National Food and Nutrition Policy with broad participation of all sectors of the Brazilian society.
As a PhD in Public Health from University of San Paolo, Dr Cointinho is primarily focused on issues relating to the promotion of healthy food habits and physical activity in the context of non-communicable disease prevention and control. As such she is a member of the World Health Organisation Expert Reference Group for WHO’s Global Strategy on Diet, Physical Activity and Health.

Professor Gordon L. Clark
Halford Mackinder Professor of Geography at the University of Oxford, Professorial Fellow of St Peter’s College, cross-appointed with the Institute of Ageing, and the Said Business School at Oxford

Professor Clark is an economic geographer with continuing interest in economic development, focusing most recently on European pensions with projects to investigate defined contribution plans in Europe and on fund trustee decision making and governance.
Professor Clark has published three books on pension related topics. His recent research has been on European pensions. His is the author of three book son pension related topics in the USA and Europe. He is also coeditor of Pension Security in the 21st Century (OUP 2003) and Oxford Handbook of Pensions and Retirement Income (with Alicia Munnell and Michael Orszag) currently being developed through Oxford University Press.

Professor Clark is on the academic panel of the UK National Association of Pension Funds and is a Governor of the Pensions Policy Institute.

Ruth Colagiuri
Director, Australian Centre for Diabetes Strategies, Sydney

Ruth Colaguiri, RN,CDE,Bed,Grad Cert Health Policy & Management is one of Australia’s foremost experts on health policy, strategic planning for population health, and health services development and research for diabetes and related chronic diseases. She has a keen interest in identifying and implementing the evidence base for health interventions; and consumer and industry participation in health policy.

She is a coauthor of the Australian National Diabetes Strategy and Implementation Plan, author of the Plan of Action for the Western Pacific Diabetes Declaration (WPDD) and is currently developing the Diabetes Strategy for sub-Saharan Africa.

Ruth is an executive member of the International Diabetes Federation -Western Pacific Regional Council and a coopted member of the WPDD Steering Committee. She is also a member of the Australian Government National Diabetes Strategies Group.
As a practitioner and senior lecturer in the Faculty of Medicine at the University of New South Wales, Ruth is a widely published author in diverse areas related to clinical care and patient education.

Professor Stephen Colagiuri
Faculty of Medicine, University of New South Wales
Chairman, Department of Endocrinology, Diabetes and Metabolism, Prince of Wales Hospital Randwick, N.S.W.

Professor Colagiuri’s research focuses on evidence based systems and standards of care, guideline development and implementation, models of care, especially in developing countries, economics of diabetes and chronic diseases
As one of the leaders in his field in Australia, Professor Colaguiri is a member of several policy setting committees. Among them are:
o Australian National Diabetes Strategy Group
o Australian Chronic Disease Prevention Alliance
o Australian National Vascular Disease Prevention Alliance.

Professor Rory Collins
Professor of Medicine and Epidemiology at the University of Oxford.
Professor Collins’ work has been in the establishment of large-scale randomised controlled trials of the treatment of heart attacks, of other vascular disease, and of cancer. He has also been involved in developing approaches to the combination of results from related randomised controlled trials (“systematic overviews” or “meta-analyses”) that allow the more reliable assessment of treatment effects.
Professor Collins qualified in medicine at St Thomas’s Hospital Medical School, University of London, with additional degrees in statistics from the USA and Oxford. He has been specialising in large scale clinical trials work since 1981at the University of Oxford.

Professor Abdallah Daar
Public Health Sciences and Surgery
Director, Program in Applied Ethics and Biotechnology, University of Toronto.
Professor Daar’s current research interests involve the exploration of how science and technology can be used to build productive innovation systems, which are linked to evolving knowledge economies in developing countries, especially in the areas of health and the environment
Educated in Uganda, London and Oxford, Professor Daar has also been active on the public health scene, having helped establish two medical schools in the Middle East, having over 250 publications, including the WHO Report on Medical Genetics and Biotechnology: Implications for Public Health.
Professor Daar is a Fellow of the New York Academy of Sciences, serves on the Ethics Committee of the Human Genome Organization and is an advisor to the Canadian Institutes of Health, Institute of Infection and Immunity.

Robert Davies
Founder and Chief Executive Officer
The Prince of Wales International Business Leaders Forum (IBLF).
The IBLF engages Chief Executive Officers and international businesses in leadership on social and development issues in over fifty countries, including health and human development, and strategies for the implementation of corporate social responsibility.
Robert’s involvement with social issues dates back to his time as a UK NHS Health Authority chairman, with primary interest in mental health and family poverty. Most recently, he has developed with WHO the dialogue with business on diet, physical activity and health and has initiated the IBLF Health Eating + Active Living (HE+AL) Partnership supported by major global companies.

Anne Duncan
LUMIU Limited.

John Elkington
Co-founder and Chair of SustainAbility
John is one of the major figures in the corporate social responsibility and sustainability fields, and has been active in shaping them for the past 30 years. He is accredited with authoring 16 books, co authoring 40 published reports and several thousand papers and articles. He is also the acknowledged inventor of such concepts as ” triple bottom line “, “green consumer ” and ” environmental excellence “, all of which have now gained legitimate currency in business thinking.
John serves on boards and advisory councils, e.g. Business & Human Rights Resource Centre (Amnesty International spin-out), Dow Jones Sustainability Indexes, Environment Foundation, Export Credits Guarantee Department (UK export credit agency) and ING. In 1989 he was elected to the UN Global 500 Roll of Honor for “outstanding environmental achievements “.

Dr. James Fries
Professor of Medicine, Stanford University.
Professor Fries introduced the hypothesis of the Compression of Morbidity in 1980, which has been gaining in currency with increasing documentation and acceptance of the paradigm. The Compression of Morbidity holds that the burden of illness may be decreased by postponement of morbidity and disability to a greater degree than life expectancy increases, compressing morbidity between a later time of onset and the age at death.
Professor Fries is a rheumatologist and internist, who has been directing the national arthritis data resource (ARAMIS) for the US National Institutes of Health for 28 years. This work is supported by longitudinal data on life quality, disability and cost outcomes in arthritis, with the risk factors for adverse and positive outcomes in chronic illness, with two longitudinal studies of aging, and concerned with the health policy implications of modelling future societies.

Daryl Ganner
Vanderbilt Diabetes Center.

Pam Garside
Management Consultant – Organisational Development in Health – New Health Group.
As a veteran of the UK NHS and with 10 years of work and study in the health sector in the USA, Pam is strongly committed to the goals of public health systems, but believes that not enough is done to maximise the contributions of the private sector.
As a management consultant, as well as a Senior Associate at the Judge Institute of Management Studies, University of Cambridge, and Co-Director of the Cambridge International Health Leadership programme, Pam sees herself as a ‘connector ‘of people and organisations.
She holds a BSc from the University of Durham and a Masters Degree in Hospital and Health Care Administration from the University of Minnesota. Pam also serves on a variety of public boards in the health arena and academia.

Sunjai Gupta
UK Department of Health.

Professor Philippe Halban
Louis Jeantet Professor of Medicine, University of Geneva
Director, Jeantet Research Laboratories.
Dr. Halban’s research has been devoted to the study of the pancreatic ß-cell and more specifically how insulin is made and secreted. His studies have helped unravel how proinsulin is converted to insulin and how the insulin is stored in granules prior to its release. Much of the knowledge gained by such studies is now being applied to the creation of surrogate ß-cells for cell replacement therapy of Type I diabetes and for the understanding of ß-cell failure in diabetic states.
He is the author of over 100 research papers and of numerous reviews and book chapters and has received several major international awards for his study of diabetes.
Dr. Halban has served as Chair of the Medical Science Review Committee of the Juvenile Diabetes Research Foundation (JDRF) and is president of the European Association for the Study of Diabetes (EASD) and of its Foundation (EFSD) for the period 2001-2004.

Christine Hancock
President, International Nurses Council
Currently, Ms Hancock is the president of the INC, which represents nurse organisations from 125 countries. This appointment follows on a full and illustrious career in clinical nursing and in public office, representing the professional and personal interests of nurses in the UK.
Some of Ms Hancock’s career highlights include:
o Chief Nurse at Bloomsbury Health Authority in central London.
o Chief Executive of Waltham Forest Health Authority in north east London, the first woman nurse to hold such a post.
o General Secretary of the Royal College of Nursing of the United Kingdom, and that for 12 years
o A member of the management committee of the King’s Fund and the health advisory committee of the British Council.
o President of the Standing Committee of Nurses of the European Union from 1995-2001.

Dr Corinna Hawkes
Project Leader – Long Term Strategy for NCD’s at the World Health Organization.
She is an honorary research fellow at the Department of Health Management and Food Policy at City University in London.
Previously she was a New York City-based freelance consultant working on food policy issues both at the international and community level.

Dr. Delon Human
Secretary General and CEO, The World Medical Association.
The WMA is a global federation of National Medical Associations representing the millions of physicians world-wide and works for the highest possible standards of medical ethics, professionalism, human rights, education and health care for all people.
As CEO, Dr Human has been in charge of the coordination of workgroups, conferences and consultations regarding the last two revisions of the Declaration of Helsinki, the cornerstone of global research ethics.
Dr Human qualified in South Africa and in Oxford and has published extensively, in addition to his current highly public role. Among others he has also served on the WHO expert panels on the development of research ethics guidelines for HIV/AIDS and general medical research.

Jeremy Hurst
Head of Health Policy Unit, Organisation for Economic Cooperation and Development (OECD)
The Health Policy Unit plays a leading role in the OECD’s Health Project the main theme of which is performance measurement and performance improvement in OECD health systems. The Unit also plays a part in maintaining and improving OECD’s Health Data files.
This position follows more than a decade of service within the UK’s NHS as a senior economic adviser during the early years of the NHS reform.
As a graduate of the London School of Economics, Mr. Hurst is a lecturer in economics at the University of Durham and has published various comparative studies on health care systems and their performance.

Corinne Husten
Centers for Disease Control & Prevention, USA.

Professor W. Philip T. James, CBE
Chair, International Obesity TaskForce.
An internationalist (worked in UK, Jamaica,USA) Professor James directed the Rowett Research Institute for 17 years. He was responsible for producing the UK Government and Royal College of Physicians, Department of Health and Scottish SIGN Guidelines reports on preventing and managing obesity.
Professor James established the International Obesity TaskForce (IOTF), which drafted the first WHO 894 Report on the obesity epidemic and undertakes a continuing programme of collaboration with WHO and expert groups worldwide.
Formerly, he produced the WHO Europe food policy report, the WHO 797 report on preventing chronic diseases, the EU BSE strategy, the report of the UN Commission on the Nutrition Challenges of the 21st century, among inumerable other policy reports for the UK governement.

Lise Kingo
Executive Vice President, Stakeholder Relations, Novo Nordisk A/S.
Ms Kingo is responsible for managing the company’s on going dialogue and relationships with stakeholders, the company’s internal programme for awareness and action in this area, and for leading Novo Nordisk toward full implementation of the Triple Bottom Line business philosophy.
A graduate of the Universities of Aarhus, Copenhagen and Bath, Ms Kingo is a member of the Board of Business for Social Responsibility in the US, and a core faculty member of HRH Prince of Wales Business and the Environment programme.

Edna Kissmann
Director, The Oxford Dialogue Project
Ms. Kissmann leads a policy and communication project under the aegis of Novo Nordisk A/S and the Oxford Centre for Diabetes, Endocrinology and Metabolism. The project (ODP) is focused on developing advocacy campaigns on behalf of people with diabetes and other chronic diseases, and will act as the Secretariat to the entire Oxford Vision 2020 3-year program.
Ms Kissmann is an international expert of healthcare communications, having led the largest healthcare communications practice for Burson Marsteller, for the last 16 years. She is currently also one of the managing partners at Kissmann Langford Ltd., a consultancy that advises CEO’s and senior management on corporate issues management and stakeholders development strategies.

Richard Laing
Project Director, Defining Methods for Setting Priorities for Pharmaceutical Research in the World
World Health Organization.
Since joining WHO in July 2003 I have worked to define methods for setting priorities for pharmaceutical research, organized a meeting about Fixed Dose combination products and have edited the Essential Drugs Monitor.
An 18-year veteran of the Health ministry of Zimbabwe, and the coordinator in US of the International network for the Rational Use of Drugs (INRUD), I have taught at Boston University, edited standard texts on Managing Drug Supply and served on myriad WHO and other committees on national drug policies.

Tim Lang
City University, London.

Arnaud Langlois
Analyst, Equity Research Department, JP Morgan’s
Mr Langlois covers the European food manufacturing and cosmetics sectors. In April 2003, he published a report on obesity (Obesity: The Big Issue), which seeks to understand the potential implications of the expansion of this non-chronic disease for the global food manufacturing industry. Arnaud’s work has generated a great deal of publicity and put obesity firmly in the minds of institutional investors.
Prior to joining JPMorgan, Arnaud worked for over three years for Societe Generale’s corporate finance department in Singapore.

Brock Leach

Dr. Stephen Leeder
Earth Institute, The Centre for Global Health and Economic Development
Columbia University.
Dr Leeder is a physician and clinical epidemiologist with a long standing research and policy interest in cardiovascular and respiratory disorders., but also with an international reputation in the study of the linkage between chronic disease and economic / social impacts in low and middle income countries
Dr Leeder is an activist whose recent report cals for urgent action to plan for, and possibly reduce, the burden of chronic diseases in the year 2020 when 1 billion people in the world will be 60+. This activism is also reflecged in his recent six year stint as the dean of the Faculty of Medicine at the Unviersity of Sydney, where he introduced a radically different medical curriculum and substantial changes in the research management policies of the university.

Dinky Levitt
University of Cape Town.

Profesor Alan Lopez
Professor of Medical Statistics and Population Health
University of Queensland.
Prior to joining Academia, Professor Lopez spent 22 years at the WHO, holding a series of senior technical and managerial positions, including that of the Chief Epidemiologist for WHO’s Tobacco Control Programme, Directorship of the Epidimeology and Burden of Disease Unit,Senior Science Advisor to the Director
He has published widely on mortality analysis and causes of death, including the impact of the global tobacco epidemic, and on the global descriptive epidemiology of major diseases, injuries and risk factors. He is the co-author of the seminal Global Burden of Disease Study (1996) which has greatly influenced debates about priority setting and resource allocation in health.

Professor David Matthews
Professor of Diabetic Medicine at the University of Oxford
Chairman of the Oxford Centre for Diabetes, Endocrinology & Metabolism.
Professor Matthews is active in research, clinical practice and teaching, and thus symbolises in his own work the motto of the Centre he heads, which is predicated on integrating these disciplines as well as the study of diabetes, metabolism and endocrine disorders.
His research covers many aspects of beta-cell function, insulin pulsatility (first describing how pulsatile insulin was more efficacious than steady-state), beta cell deterioration (describing the coefficient of failure) and many aspects of the function of secretagogues.
Professor Matthews has interests in mathematical modelling of insulin resistance and beta-cell function and first described the HOMA model in 1985. He has wide interests in therapeutics in diabetes, with publications relating to thiazolodinediones and GLP-1.
Professor Matthews is a well known clinician in diabetes medicine; he also plays an active role in assessing the impact of diabetes and holds a Wellcome Trust grant undertaking the oral history of diabetes.
Professor Matthews teaches and lectures widely in the UK and internationally. He is on the board of several medical journals, is past chairman and a current trustee of the Grants Committee of Diabetes UK.

Professor Martin McKee
Professor of European Public Health, London School of Hygiene and Tropical Medicine
Director, European Centre on Health of Societies in Transition
Professor McKee manages a large research programme on health and health care involving many countries in Europe. His work has contributed substantially to understanding the fluctuations in mortality in the former Soviet Union since the mid 1980s.
He has published over 280 papers in academic journals and written or edited 11 books. In 2003 he was awarded the Andrija Stampar medal for his contributions to European public health. He is also just completed his stint as Editor in Chief of the European Journal of Public Health.

The Rt. Honourable Alan Milburn, MP
Alan has been Member of the UK Parliament for Darlington since 1992, and until earlier this year was the Secretary of Health in the Blair cabinet from 1999. Before this appointment, Alan served the cabinet as the Chief Secretary to the Treasury, and was also a Health Minister on the front bench.
Before being elected for Parliament, Alan worked in business development and for a trade union research centre. He co-ordinated the Sunderland Shipyards Campaign in 1988.
Alan’s special interests are health, the economy, regional policy and crime. He has been in charge, for the past 4 years until leaving office, of the most ambitious reform plans for the UK’s NHS – one of the largest healthcare systems in the world, and one of the largest employers in Europe.

Dr. Daniel S. Miller
Liaison from the Office of the Director to the World Bank
Centers for Disease Control, USA.
Dr Miller is an experienced physician in maternal and child health, who also posses a Masters in Public Health and a Preventive Medicine specialization.
Dr Miller has worked in the private sector as Medical Director for a network of primary care clinics for low income families in Seattle, before joining the CDC. There, he has fulfilled a variety of important tasks, in the Nutrition and Cancer Prevention and Control Division.
As an expert in medical and nutrition relief in conflict situations, Dr Miller advises the World Bank on essential public health functions, surveillance, chronic diseases and primary health, for the entire bank’s Client Countries in East Europe, Central Asia and South East Asia.

Dr. Alfredo Morabia
Professor and Director of the Division of Clinical Epidemiology
University Hospitals in Geneva.
Since 1991 Professor Morabia has been checking the health and life habits of by now more than 10,000 randomly selected people. The BUS Sante Survey has been reporting on the long term trends in risk factor prevalence in the Geneva population
Professor Morabia has also been coordinator of EURALIM, a European Community funded project aiming at harmonizing survey data across some European countries.

Harriet Mouchly-Weiss
Strategy XXI Group LTD.

Bruce Neal
University of Sydney.

Dr. Sania Nishtar
Founder and President, Heartfile.
Dr. Nishtar scope of work, currently in the area of non communicable diseases, is influencing health policies at a global level, reorienting them in the wake of the world-wide epidemiological transition in health. In addition, she is actively engaged in the creation, implementation and evaluation of public health programs and models relevant to low resource settings.
This focus in reflected in her brainchild and work with Heartfile in Pakistan, a public health initiative for advocacy, community health interventions and reorientation of health services in Pakistan; a model being replicated in several other developing countries.
Recently, Dr Nishtar was appointed as the chair of the National Action Plan for the Prevention and Control of Non Communicable Diseases in Pakistan. Through this program, she has engineered the development of the first tangible Public Private Partnership in the health sector in Pakistan.
Dr Nishtar’s impact spans 6 continents; from capacity building of African, Eastern European and Asian Heart Foundations and networks in collaboration with major international health agencies, to advising Governments, to defining the relationship between poverty and health, to developing and implementing the concept of franchising in health.

Tom Novotny
University of California at San Francisco.

Dr. Junko Otani
Medical Officer in charge of Noncommunicable Diseases at World Health Organization (WHO) Representative China Office.
While the burden of NCD is significant in China, a mega-country in transition with a rapidly ageing population, the area within WHO China is new, and I am trying to build it up with our very limited resource.
As I may be the only Japanese at the group, I hope I will be able to contribute from the views of Japan, my home country, as well.
Academic background: Doctor of Dental Surgery from Osaka, Japan. Master of Public Health in International Health and Population from Harvard. PhD in Social Policy in Ageing from London School of Economics and Political Science.

Sir Richard Peto
University of Oxford.

Stavros Platakis
Novo Nordisk Europe.

Dr. Stig Pramming
Vice President, Global Health, Novo Nordisk A/S.
Principal Organiser – Oxford Vision 2020 process.
As the primary director in charge of relationships with key opinion leaders and IGOs and NGOs in the fields of global health and diabetes, Dr Pramming is one of the founding partners of the Oxford Vision 2020 process. This program is part of the company’s vision to eradicate diabetes and build a better health system in the future for people with diabetes and other chronic diseases.
Dr. Pramming is a specialist in internal medicine who is still practicing from time to time. He is also a widely published author with 50+ papers to his name, and several co authorships of professional text books. His previous experiences at Novo Nordisk, in clinical development, marketing, public affairs and stakeholder relations, and his consulting privileges at the Oxford Centre for Diabetes, Endocrinology and Metabolism, provide ample background to the current focus on fighting chronic diseases on a global basis.

Erik Rasmussen
Founder, Editor in Chief and CEO of the House of Monday Morning.
A journalist by avocation and training, Mr Rassmussen spent his entire career in the media.
Mr. Rasmussens carrier embraces:
o Economic Editor of Berlingske Aftenavis
o Editor in Chief of the financial daily Børsen
o Managing Director of the publishing company of Gutenberghus
o Editor in Chef of the publishing company Management
o Editor in Chief of Børsens Nyhedsmagasin
o Chief of the think tank Forum for Industrial Development.

Dr. Scott C. Ratzan
Vice President, Government Affairs, Johnson & Johnson Europe
Dr. Ratzan’s most recent position was as Senior Technical Adviser in the Bureau of Global Health at the United States Agency for International Development, (USAID), where he developed the global health communication strategy for U.S. funded efforts in 65 countries for the next decade.
Following a decade in Boston (1988-1998) in academia as founder and Director of the joint master’s program at Emerson-Tufts on Health Communication, Dr. Ratzan still continues to lecture at Yale University School of Medicine, Tufts University School of Medicine and George Washington University Medical Centre as well as the College of Europe in Belgium.

Dr. William (Bill) Robert Rowley
MD, Senior Medical Futurist, Institute for Alternative Futures.
Dr Rowley’s career spans many important milestone, but true to his military background they are represented herein concisely:
– Vascular surgeon
– Associate professor of surgery
– Academic medical center chief executive officer
– Navy Admiral
Currently a medical futurist aspiring to improve health and healthcare.

Tony Scullion
CEO, Memory Pharmaceuticals Corporation
I have 27 years of strategic and operational experience, at senior levels, in R&D based multinational Pharmaceuticals Companies. For the past 2 years I have been CEO of an innovative R+D based biotechnology Company.
I spent 16 years with Pfizer living and working in Europe, the US and Asia. In 1993 I joined Glaxo as Head of Global Business Development responsible for Global research and commercial alliances with academia, biotech and other companies. In my role as a member of GlaxoWellcome’s Management Committee and Commercial Operations Committee I became the company’s expert on the tough topic of alliance management.
30 years in the Pharmaceutical Industry with operational experience in both developed and developing countries have provided considerable experience in the practical issues surrounding innovation, healthcare economics and treatment accessibility.

Imogen Sharp
Director, Health Improvement and Prevention, UK’s Department of Health
Ms Sharp has triple responsibilities: development and delivery of Department of Health plans in the priority areas of tobacco, obesity, diet and exercise, hypertension prevention, accidental injury and complementary medicine. She is also responsible for delivering on the NHS plan commitments by government, and the prevention elements of the National Service Frameworks
She has been instrumental in establishing the Five a Day Programme and National School Fruit scheme in England. She is also a member of the World Health Organisation Expert Reference Group for its Global Strategy on Diet, Nutrition and Physical Activity.
She previously directed the National Heart Forum and established it as the leading national alliance on CHD prevention – including medical, health, consumer and research bodies – over a period of 12 years.

Barbara Smith
Independent consultant, Communication and Innovation.
Highly experienced and versatile facilitator of innovation in companies and social organisations, with global experience and work knowledge of business in the USA, Europe and Asia
Prior to her setting up on her own, Barbara was (respectively) the Chief Learning Officer and the Chief Creative Office of one of the largest communications firms in the world. In both capacities, she was responsible for sharing the skills and knowledge of the organisation; as well as developing powerful campaigns on behalf of client issues and products.

Dr. Krisela Steyn
Director of the Chronic Diseases of Lifestyle Unit — Medical Research Council,
Director of the WHO Collaborating Centre on Chronic Diseases of Lifestyle, South Africa.
Dr Steyn’s research interests include the community health aspects of chronic diseases of lifestyle and clinical aspects of hyperlipidaemia and hypertension. In addition she is involved in research capacity development for chronic diseases of lifestyle, particularly for researchers from disadvantaged
She has published 86 papers in indexed journals, and 56 other papers. Her presentations at scientific meetings nationally and internationally total 156. As such, she often acts as a consultant to a variety of governments, NGO’s and international organisations.

Dr. Marc Suhrcke
Scientist (Economic Development) — WHO European Office for Investment for Health and Development (Venice, Italy).
Previous professional experiences: UNICEF Innocenti Research Centre (Florence, Italy), Hamburg Institute for International Economics, European Bank for Reconstruction & Development (London), European Commission (Brussels), Center for European Policy Studies (Brussels), University of Hamburg. Academic background: PhD in Economics from University of Hamburg.

Lars Rebien Sørensen
President and CEO, Novo Nordisk A/S
Following 18 years of service within the company, first in the Novo Nordisk enzymes business, then in a variety of marketing and sales functions in several countries, and laterally as a special emissary from the Board of Directors to turnaround the healthcare business, he was appointed as president and CEO in November 2000.
Mr Sorensen is responsible for all company operations, marketing, sales, profit performance and reputation, working with a small executive management group and many heads of the various Novo Nordisk affiliates around the world. He is also a member of the Board of Scandinavian Airlines System AB and ZymoGenetics, Inc.

Sophia Tickell
Director, Pharma Futures Project.
As a social and economic historian, Sophia Tickell has worked on international development throughout her career, first on the ground for 6 years in Bolivia, and then as a senior policy advisor on the private sector at Oxfam headquarters. There she co-authored several reports: on GSK, on Pfizer and the Oxfam Coffee Report, which put her at the forefront of the campaign to reverse private sectors priorities in the developing world
Sophia Tickell is a member of several advisory committees, including the Global Compact Advisory Board and the pharmaceutical Shareholder group advisory committee, and is also a Council Member of SustainAbility.

Colin Tukuitonga
World Health Organization.

Dr. Mikko Vienonen
Special Representative of the WHO Director General in Russia.
After ten years as a “country doctor” I became responsible in MoH (Finland) for PHC, especially MCH, school health and family planning. I have acquired specialties also in health administration and in international public health.
From 1999 I have been working as the head of the WHO Office in Moscow. This post entails a broad range of assistance to Russia in humanitarian and developmental issues.
MOTTO: It is not so important from which direction the wind is blowing. It is more important how you trim your sails.

Este Vorster
University Potchefstroom.

Janet Voûte
Chief Executive Officer, World Heart Federation.
Janet is responsible for strategic planning, corporate partnerships, development, marketing, communications, finance and Information Technology as well as being actively involved in global advocacy efforts. She firmly believes that through public/private partnerships, major global challenges can be overcome.
Always the internationalist (MA in International Politics and Economics from John Hopkins University), Janet brings to her new avocation extensive experience from the management consulting field (Bain & Company), from the world of finance and industry (venture capitalist and strategic planner, Pepsi Cola and EuroVentures), and the dedication to the health needs of the developing countries (Board Director of Project HOPE, Switzerland.)

Derek Wanless
HM Treasury, UK.

Amalia Waxman
Project Manager of the WHO Global Strategy on Diet, Physical Activity and Health.
The Global Strategy, developed on the basis of wide ranging consultation with public and private stakeholders, is expected to be approved by WHO Executive Board in January 2004 and endorsed then by The World Health Assembly in May 2004.
Prior to her work in WHO, Amalia Waxman was policy and legislation coordinator in the Israeli Women’s Network, a non-profit advocacy organization promoting women’s rights through legislation and legal appeals. In this capacity Amalia served at the key contact between legislators in the Israeli parliament and women’s organizations.

Bo Wesley
Manager – Stakeholder Relations, Novo Nordisk A/S
Principal Organiser – Oxford Vision 2020 process.
Mr Wesley is responsible for a variety of projects around planning the future business models for the company, as well as ensuring its reputation and role in society.
The projects cover a wide range of activities, from the development of scenarios, the spotting of trends through internet monitoring and bespoke research, conducting stakeholder dialogue activities, of which the Oxford Vision 2020 is one, and running internal innovation and learning programs for the board of directors and top management. Mr Wesley has a MSc in Economics.

Thomas West
LifeScan – Europe, Middle East & Africa.

Julie Whittaker
Manager, The Oxford Dialogue Project.
Ms. Whittaker project manages a policy and communication project under the aegis of Novo Nordisk A/S and the Oxford Centre for Diabetes, Endocrinology and Metabolism. The project (ODP) is focused on developing advocacy campaigns on behalf of people with diabetes and other chronic diseases, and will act as the Secretariat to the entire Oxford Vision 2020 3-year program.
Ms Whittaker worked as practice business manager for Burson Marsteller, a global communications firm, for the previous 7 years. Ms Whittaker is politically active with the Liberal Democrat party in the UK.

Dr. Derek Yach
Representative of the Director General, World Health Organization
For two decades I have initiated, managed and implemented several epidemiological and policy related research projects and programs in priority public health areas at the national and international level.
At WHO my work initially involved conducting a critical assessment of the successes and failures of the Health for All strategy, and execution of an extensive global consultative process to develop a “renewed” Health for All (HFA) policy.
From May 1998, I started work on WHO’s first international treaty, the Framework Convention on Tobacco Control (FCTC). After five years of complex international negotiations, the FCTC was adopted in May 2003 by all WHO’s 192 member states.
For the last three years, as Executive Director, I directed development of a Global Strategy for diet, physical activity and health. Currently, I have responsibility for developing a new NCD strategy for WHO.

Michael (Mick) Yates
Partner, Visionary Thinking Ltd.
The Visionary Partnership of former CEOs helps build global brands – products, services and companies – with tailored approaches to strategy, innovation and leadership across country and cultural boundaries.
Previously Mick was Company Group Chairman of Johnson & Johnson’s Consumer business in Asia-Pacific, based in Singapore. Earlier Mick spent 22 years at Procter & Gamble Asia, in all he spent 11 years as a Regional CEO of Asian businesses, and before that several years as a General Manager in Europe and the USA.
Mick and his wife started an education program in the ex Khmer Rouge areas of Cambodia, now in its 5th year. He is a Board Trustee of Save the Children USA, on the Board of Directors of Save the Children Korea, and an advisor to the International Save the Children Alliance in London.
He is founder of, one of the internet’s busiest leadership development sites.